Abeona Therapeutics (United States)

Recent papers from Abeona Therapeutics (United States)

1. Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trialThe Lancet · 2025
2. Danburstotug, an anti‐ PD ‐ L1 antibody, in relapsed/refractory extra‐nodal natural killer/T‐cell lymphoma: The phase 2 DISTINKT studyBritish Journal of Haematology · 2026
3. A radiolabeled dendrimer non-invasively identifies and tracks innate immune cell activation in a mouse model of experimental autoimmune encephalomyelitisNature Communications · 2026
4. OcuPair, a Novel Photo‐crosslinkable PAMAM Dendrimer‐Hyaluronic Acid Hydrogel Bandage/Bioadhesive for Corneal Injuries and Temporary Corneal RepairAdvanced Science · 2025
5. FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical modelsCommunications Medicine · 2025
6. OcuPair, a novel photo-crosslinkable dendrimer-hyaluronic acid hydrogel bandage/bioadhesive for corneal injuries and temporary corneal repair2025
7. Kinetic and Mechanistic Studies of Human Oligoadenylate Synthetase 1Biochemistry · 2024
8. Targeting the synthetic lethal relationship between FOCAD and TUT7 represents a potential therapeutic opportunity for TUT4/7 small molecule inhibitors in cancerMolecular Cancer Therapeutics · 2024
9. EHMT1/2 inhibition promotes regression of therapy-resistant ovarian cancer tumors in a CD8 T cell-dependent mannerMolecular Cancer Research · 2024
10. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune ActivationMolecular Cancer Therapeutics · 2024
11. Selective targeting and modulation of plaque associated microglia via systemic hydroxyl dendrimer administration in an Alzheimer’s disease mouse modelAlzheimer s Research & Therapy · 2024
12. Development and initial assessment of [18F]OP-801: a novel hydroxyl dendrimer PET tracer for preclinical imaging of innate immune activation in the whole body and brain2023
13. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosaOrphanet Journal of Rare Diseases · 2022
14. Bayesian model of disease progression in mucopolysaccaridosis IIIAStatistics in Medicine · 2022
15. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosaOrphanet Journal of Rare Diseases · 2021
16. A computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action2021
17. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidityEmerging Microbes & Infections · 2020
18. From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Clinical Cosmetic and Investigational Dermatology · 2019
19. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosaJCI Insight · 2019
20. Scalable synthesis and validation of PAMAM dendrimer‐N‐acetyl cysteine conjugate for potential translationBioengineering & Translational Medicine · 2018